Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

NCT06452433 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: gumarontinib
DRUG: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences